European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat
November 16, 2021 08:30 ET
|
SIGA Technologies Inc.
- Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications - NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a...
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
November 04, 2021 16:05 ET
|
SIGA Technologies Inc.
- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - - Approximately $13 Million of International Sales for the First Nine Months of...
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
October 28, 2021 16:15 ET
|
SIGA Technologies Inc.
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
September 13, 2021 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of a procurement option under its...
SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021
September 07, 2021 13:16 ET
|
SIGA Technologies Inc.
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company’s Chief...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021
August 05, 2021 16:15 ET
|
SIGA Technologies Inc.
- Approximately $7 Million in International Sales of Oral TPOXX® in the Second Quarter – - Authorization of Additional $50 Million Share Repurchase Program - - Corporate Update Conference Call...
SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results
July 29, 2021 16:15 ET
|
SIGA Technologies Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
July 29, 2021 03:30 ET
|
SIGA Technologies Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom
June 30, 2021 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Reports Financial Results for Three Months Ended March 31, 2021
May 06, 2021 16:05 ET
|
SIGA Technologies Inc.
- Approximately $3 Million in International Sales of Oral TPOXX® in the First Quarter - - Approximately $7 Million in International Sales of Oral TPOXX® in April - - Corporate Update Conference...